In this context, the FLT4 antagonist, MAZ51, significantly reduced peri- and intratumoral melanoma cells’ proliferation by decreasing the number of lymphatic vessels and capillaries into mice lungs with induced melanoma [42]. Here, FLT4 is linked to melanoma.